![](/images/graphics-bg.png)
Comparison of oral recombinant erythropoietin and subcutaneous recombinant erythropoietin in prevention of anemia of prematurity
المؤلفون المشاركون
Gholami, M.
Saeidi, R.
Bani Hashim, A.
Hammoud, M.
المصدر
Iranian Red Crescent Medical Journal
العدد
المجلد 14، العدد 3 (31 مارس/آذار 2012)، ص ص. 178-181، 4ص.
الناشر
تاريخ النشر
2012-03-31
دولة النشر
الإمارات العربية المتحدة
عدد الصفحات
4
التخصصات الرئيسية
الموضوعات
الملخص EN
Background: Premature neonates are at risk for severe anemia and erythropoietin is the most important hormone in erythropoiesis.
The aim of this study was to evaluate the influence of oral recombinant human erythropoietin (rhEPO) in proving erythropoiesis in neonates.
Methods: This was a randomized clinical trial study.
Thirty neonates were enrolled from September 2007 to September 2008.
The first group received oral rhEPO and Fe and the second, subcutaneous rhEPO and Fe.
The patients’ Hb, HCT and the need to blood transfusion were recorded.
We included all infants with gestational age <34 weeks, birth weight <1500 gr, without respiratory distress (O2 Saturation> 85%, FiO2 of 30%), full feeding tolerance so that oral Fe can be administrated.
Results: In first group (oral=PO), 65% of neonates were female and 35% were male, mean weight was 1140 g and mean GA was 32.6 weeks.
In the second group (subcutaneous=SC), 42% were female and 58% were male.
The mean weight was 1245 g and mean GA was 31.2 weeks and this was not statistically significant.
In the first group, the mean Hb and HCT were 9.7±1.9 and 29.6±5.9 g/dl.
In the second group, the figures were 12.5±1.7 and 38.8±5.1 which were statistically significant.
There was no difference in the weight gain between two groups.
In the first group, 3 neonates (20%) and in the second one, 1 neonate (15%) needed blood transfusion.
Conclusions: rhEPO administration either PO or SC could prevent anemia of prematurity but SC rout was more effective.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Saeidi, R.& Bani Hashim, A.& Hammoud, M.& Gholami, M.. 2012. Comparison of oral recombinant erythropoietin and subcutaneous recombinant erythropoietin in prevention of anemia of prematurity. Iranian Red Crescent Medical Journal،Vol. 14, no. 3, pp.178-181.
https://search.emarefa.net/detail/BIM-311748
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Saeidi, R.…[et al.]. Comparison of oral recombinant erythropoietin and subcutaneous recombinant erythropoietin in prevention of anemia of prematurity. Iranian Red Crescent Medical Journal Vol. 14, no. 3 (Mar. 2012), pp.178-181.
https://search.emarefa.net/detail/BIM-311748
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Saeidi, R.& Bani Hashim, A.& Hammoud, M.& Gholami, M.. Comparison of oral recombinant erythropoietin and subcutaneous recombinant erythropoietin in prevention of anemia of prematurity. Iranian Red Crescent Medical Journal. 2012. Vol. 14, no. 3, pp.178-181.
https://search.emarefa.net/detail/BIM-311748
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 181
رقم السجل
BIM-311748
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)